Significantly lower risk is seen for mortality, ventilation, hospitalization, recovery, and viral clearance. 4 studies from 2 independent teams in 2 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 78% [70‑83%] lower risk. Results are similar for peer-reviewed studies. Currently all studies are RCTs.
Studies to date are from only 2 different groups.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. All data and sources to reproduce this analysis are in the appendix.
Zheng et al. present another meta analysis for proxalutamide, showing significant improvements for mortality, mechanical ventilation, hospitalization, and clinical improvement.
Covid Analysis et al., Jan 2025, preprint, 1 author.
